• We The Patients Fly-In
  • Events Calendar
0 Items
Patients Rising Now
  • Home
  • About
    • About Us
    • Partners and Coalitions
    • Corporate Membership
    • Corporate Members
    • Financials
  • Issues
    • Terry’s Hot Take
    • News and Insights
    • Positions
    • Policy Supported
  • Take Action
  • Donate
Select Page
  • Home
  • About
    • About Us
    • Partners and Coalitions
    • Corporate Membership
    • Corporate Members
    • Financials
  • Issues
    • Terry’s Hot Take
    • News and Insights
    • Positions
    • Policy Supported
  • Take Action
  • Donate

Federal Issues

Why We Need Patient Diversity in Clinical Trials

Why We Need Patient Diversity in Clinical Trials

Apr 21, 2022 | Federal Issues

By Surabhi Dangi-Garimella, PhD Diversity presents facts. Diversity provides a true reflection of reality, and this holds true for clinical trials as well. The FDA’s Office of Minority Health and Health Equity is a big proponent of diversity among clinical trial...
Read more
MDUFA Up for Renewal, Congress Recommends a Facelift

MDUFA Up for Renewal, Congress Recommends a Facelift

Mar 21, 2022 | Federal Issues

By Surabhi Dangi-Garimella, PhD User fee agreements—whether for a medical device or a prescription drug—create a path for manufacturers to get their product reviewed in a systematic manner by the FDA. The Medical Device User Fee and Modernization Act of 2002, known as...
Read more
Season 3 | Episode 8: Speedy Rare Disease Drug Reviews

Season 3 | Episode 8: Speedy Rare Disease Drug Reviews

Feb 28, 2022 | Featured, Federal Issues

On this episode of the podcast, Terry and Bob discuss accelerated drug review for rare diseases. This topic coincides with Rare Disease Day on February 28. With the Prescription Drug User Fee Act (PDUFA) up for renewal in Congress, much is at stake for the rare...
Read more
Telehealth Policies Needed to Address America’s Digital Healthcare Divide

Telehealth Policies Needed to Address America’s Digital Healthcare Divide

Feb 24, 2022 | Featured, Federal Issues

By Surabhi Dangi-Garimella, PhD The 21st Century Cures Act is being rekindled: introduced in Congress in November 2021, CURES 2.0 proposes to upgrade several areas of the U.S. healthcare system, one of which is telehealth. The Telehealth Modernization Act includes...
Read more
CURES 2.0 Proposes New Agency for Health, Expansion of Medicare’s Telehealth Services

CURES 2.0 Proposes New Agency for Health, Expansion of Medicare’s Telehealth Services

Feb 8, 2022 | Federal Issues

By Surabhi Dangi-Garimella, Ph.D. Advanced Research Projects Agency for Health (ARPA-H)—that’s the name of the new $6.5 billion agency being proposed as part of the next iteration of the 21st Century Cures Act (CURES 2.0). Along with an infusion of funding into the...
Read more
Right to Repair: A Catch-22 for Patient Health

Right to Repair: A Catch-22 for Patient Health

Jan 31, 2022 | Federal Issues, Health Policy

By Surabhi Dangi-Garimella, Ph.D.  Repair restrictions by equipment manufacturers remains a significant issue that spans industries and is relevant to consumer protection and antitrust issues related to repair restrictions—be it phone or car manufacturers or...
Read more
« Older Entries

Categories

  • Access
  • Actions
  • California
  • Copay Accumulators
  • Copay Assistance
  • COVID-19
  • Drug Costs
  • FDA
  • Featured
  • Featured Action
  • Federal Issues
  • Health Insurance
  • Health Policy
  • ICER
  • Illinois
  • Issues
  • Letters Submitted
  • Letters Supported
  • Massachusetts
  • Medicaid
  • Medicare
  • Medicare Part D
  • News
  • Op-Ed
  • Out of Pocket Costs
  • Pharmacy Benefit Managers
  • Podcast
  • Prescription Drugs
  • Press Releases
  • Public Statement
  • QALY
  • State Issues
  • Statements
  • Step Therapy
  • Surprise Billing
  • Terry's Hot Take
  • Uncategorized
  • Value Based Insurance Design
  • Value Frameworks
  • Virtual Advocacy Chat

Tags

21st Century Cures Act 340B Access to Care Advocacy Alzheimer's Biden Administration biosimilars Cancer cms Copay Accumulators copay assistance COVID-19 Vaccine drug costs Drug Manufacturing Drug Pricing drug rebate fail first FDA H.R.3 Healthcare Inequities Health Insurance hospital bills HR 3708 hsa ICER Insurance design Joe Biden Lupus medicare Part B medicare part D Mental Health Nonmedical Switching open enrollment Out of Pocket Costs PBM pharmacy benefit managers Price Transparency Prior Authorization QALY Rare Disease Right to Repair Step Therapy Telehealth transparency Value Framework

Recent Posts

  • Can Mark Cuban Deliver Cheaper RX? – Season 3 | Episode 20
  • What is the Future of Co-pay Accumulator and Maximizer Programs? 
  • Have Health Plans Abandoned Rare Disease Patients?: Season 3 | Episode 19
  • Patients Rising Now Pens Letter Regarding S.2910: The Expanding Access to Low-Cost Generics Act of 2021
  • OIG Report Tags Biosimilars for Medicare and Beneficiary Savings

Sign up for updates

Patients Rising Now

We are a 501c4 group dedicated to demanding transparency in health care.  We are part of the Patients Rising suite of programs and services.

700 12th St. NW 700, Suite 700
Washington, DC 20005

  • Privacy Policy
  • Sponsor Opportunities
  • Patients Rising
  • Facebook
  • Twitter
  • Instagram
All rights reserved. © 2022 Patients Rising Now